30 min listen
Gene testing for all breast cancer patients with second primary malignancy, atezolizumab for TNBC, pralsetinib for NSCLC, and more
FromBlood & Cancer
Gene testing for all breast cancer patients with second primary malignancy, atezolizumab for TNBC, pralsetinib for NSCLC, and more
FromBlood & Cancer
ratings:
Length:
12 minutes
Released:
Sep 15, 2020
Format:
Podcast episode
Description
Hematology/Oncology News: Study supports multigene panel testing for all breast cancer patients with second primary cancers: https://bit.ly/3m6RyOGSource: https://bit.ly/2ZKXund Atezolizumab TNBC indication ‘in jeopardy’ because of phase 3 results: https://bit.ly/35rqzrl Alert: https://bit.ly/2Reh1HMTrial: https://bit.ly/2ZqqIqX Pralsetinib: Second drug for RET+ NSCLC approved in U.S.: https://bit.ly/3bTdGaz Unexpected results in new COVID-19 ‘cytokine storm’ data: https://bit.ly/3k8fIGL JAMA research letter: https://bit.ly/35ubxB4 You can email the show at podcasts@mdedge.com
Released:
Sep 15, 2020
Format:
Podcast episode
Titles in the series (100)
Common bleeding and coagulation issues: There’s an art to taking a thorough bleeding history. In this episode, , director of the Hemophilia and Thrombosis Center at the University of Pennsylvania, Philadelphia, shares the most important questions to ask and the challenges in assessing... by Blood & Cancer